Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CACIPLIQ20 in Wound Healing for Epidermolysis Bullosa
NCT06007235Recruiting
- Start
- Jan 2024
- Primary completion
- Sep 2024
- Modality
- Polymer-based Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Randomised, double-blind trial in dystrophic epidermolysis bullosa (DEB) and junctional epidermolysis bullosa (JEB) comparing CACIPLIQ20 first with Placebo first (2 arms). Primary endpoint: Change in total lesioned skin surface at 1 month. Started Jan 2024; status: recruiting.
02
Drugs
CACIPLIQ20
03
Conditions
dystrophic epidermolysis bullosa (DEB)junctional epidermolysis bullosa (JEB)
Beyond the preview
Go deeper on NCT06007235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007235.